Deregulation of Rho GTPases in cancer
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
In vitro and in vivo studies and evidence from human tumors have long implicated Rho GTPase signaling in the formation and dissemination of a range of cancers. Recently next generation sequencing has identified direct mutations of Rho GTPases in human cancers. Moreover, the effects of ablating genes encoding Rho GTPases and their regulators in mouse models, or through pharmacological inhibition, strongly suggests that targeting Rho GTPase signaling could constitute an effective treatment. In this review we will explore the various ways in which Rho signaling can be deregulated in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
RHO GTPASES: Biochemistry and Biology
Jaffe, A. B., & Hall, A. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.020604.150721 · Cited by 3,009 · cited 1×
“tion and maintenance of stem cells in the bone marrow, skin and intestine.(2,3,5) Conversely, deregulation of Rho GTPases is linked to many of the “hallmarks of cancer,” including oncogenic transformation, cell survival and tumor metabolism as well as metastasis (reviewed in ref.”
BackgroundA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · cited 4×
“substituting Proline (P) with Leucine (L) (P29L mutation).(93) Two Rac2 mutations - P29L and P29Q – similar”
BackgroundInfluentialGEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors
Rossman, K. L., Der, C. J., & Sondek, J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1587 · Cited by 1,697
Regulation of Small GTPases by GEFs, GAPs, and GDIs
Cherfils, J., & Zeghouf, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00003.2012 · Cited by 1,245
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191 · cited 1×
“It was first identified by 2 groups in 2012.(93,94) Whole-exome sequencing was performed in melanoma”
BackgroundRational design and characterization of a Rac GTPase-specific small molecule inhibitor
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307512101 · Cited by 1,091 · cited 4×
“independent growth and invasion of prostate cancer cells.(117) Rac1 inhibition can additionally reduce”
BackgroundInfluentialMelanoma genome sequencing reveals frequent PREX2 mutations
Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., Ivanova, E., Watson, I. R., Nickerson, E., Ghosh, P., et al. (2012) · Nature · doi:10.1038/nature11071 · Cited by 756 · cited 1×
“Overexpression of the Rac1 GEF P-Rex1 promotes metastasis of prostate cancer(49) and mutations have been identified in PREX2 (a Rac GEF) in melanoma.(50) Tiam1,”
Background
Cited by
Rho GTPases: Regulation and roles in cancer cell biology
Haga, R. B., & Ridley, A. J. (2016) · Small GTPases · doi:10.1080/21541248.2016.1232583 · Cited by 559
Mutational drivers of cancer cell migration and invasion
Novikov, N. M., Zolotaryova, S. Y., Gautreau, A. M., & Denisov, E. V. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01149-0 · Cited by 302
Identification of cancer driver genes based on nucleotide context
Dietlein, F., Weghorn, D., Taylor-Weiner, A., Richters, A., Reardon, B., Liu, D., Lander, E. S., Van Allen, E. M., & Sunyaev, S. R. (2020) · Nature Genetics · doi:10.1038/s41588-019-0572-y · Cited by 255
Müller, P. M., Rademacher, J., Bagshaw, R. D., Wortmann, C., Barth, C., van Unen, J., Alp, K. M., Giudice, G., Eccles, R. L., Heinrich, L. E., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0488-x · Cited by 253
Regulation of RhoA GTPase and various transcription factors in the RhoA pathway
Kim, J., Islam, R., Cho, J. Y., Jeong, H., Cap, K., Park, Y., Hossain, A. J., & Park, J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26487 · Cited by 131
Metadata
- Authors
- Porter, A. P., Papaioannou, A., & Malliri, A.
- Venue
- Small GTPases
- Publisher
- Informa UK Limited
- Published
- 2016-04-22
- Volume
- 7
- Issue
- 3
- Pages
- 123-138
- ISSN
- 2154-1248 (ISSN-L)
- 2154-1256
- OpenAlex
- W2340039096
- Cited by
- 194
- References
- 16
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deregulation of Rho GTPases in cancer. https://app.cochat.ai/papers/10.1080/21541248.2016.1173767
- The paper
- Porter, A. P., Papaioannou, A., & Malliri, A. (2016). Deregulation of Rho GTPases in cancer. Small GTPases. https://doi.org/10.1080/21541248.2016.1173767
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.